A股異動 | 華誼兄弟(300027.SZ)領漲影視股 《八佰》票房突破13億
格隆匯8月27日丨華誼兄弟(300027.SZ)以6.26%的漲幅領漲影視股。據貓眼專業版實時數據顯示,截至今日7:40,電影《八佰》上映第7日票房突破13億元至13.2億元。《八佰》的主要投資方為華誼兄弟,聯合出品方包括阿里影業(同時也是發行方)、光線傳媒、上海電影、騰訊影業等。對於《八佰》的上映,不少機構給予高度看好,普遍預期票房會在20億元-30億元。 另一部熱門電影《我在時間盡頭等你》上映第3日票房突破3億元至3.25億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.